Resmetirom Cuts CV Risk in MASH: Meena Bansal, MD

Why It Matters

Cardiovascular disease drives mortality in MASH, and resmetirom’s ability to lower LDL‑C and Lp(a) beyond statins offers a new avenue to cut that risk. Routine Lp(a) testing and multidisciplinary clinics could enable earlier intervention and improve survival.

Key Takeaways

• Resmetirom lowers LDL‑C, ApoB, and Lp(a) in MASH patients
• Lipid benefits persist even when patients are on statins
• Study urges routine Lp(a) testing in hepatology clinics
• Integrated liver‑cardio clinics recommended for comprehensive MASH care

Pulse Analysis

Metabolic dysfunction‑associated steatohepatitis (MASH) has emerged as a dual‑threat condition, combining progressive liver injury with a markedly elevated cardiovascular risk profile. Traditional management has focused on liver endpoints, while statins remain the cornerstone of lipid control. However, patients with MASH often exhibit residual atherogenic dyslipidemia—particularly elevated lipoprotein(a) (Lp[a])—that is poorly responsive to statins alone, leaving a gap in cardiovascular protection that clinicians are eager to fill.

Resmetirom’s mechanism of selectively activating thyroid hormone receptor‑β in the liver drives upregulation of LDL receptors and curtails secretion of ApoB‑containing lipoproteins, pathways distinct from the HMG‑CoA reductase inhibition of statins. The secondary analyses of the MAESTRO‑NASH and MAESTRO‑NAFLD‑1 trials revealed consistent reductions in LDL‑C, ApoB and Lp(a) regardless of baseline statin use, while liver histology endpoints remained robust. This additive lipid‑lowering effect is especially compelling for Lp(a), a particle largely resistant to conventional therapy and a known driver of both atherosclerosis and thrombosis in the MASH population.

The clinical implications are twofold. First, routine Lp(a) screening should become standard in hepatology practices to identify patients with hidden residual risk. Second, the data support the creation of integrated MASH clinics that bring together hepatologists, cardiologists, endocrinologists and dietitians to coordinate liver and cardiovascular treatment goals. As RNA‑based Lp(a)‑lowering agents move toward market, the ability of resmetirom to already blunt Lp(a) levels positions it as a strategic bridge therapy, potentially reshaping both drug development pipelines and reimbursement models for this high‑risk cohort.